AtriCure, Inc. vs. Boston Scientific Corp.
Boston Scientific Corp. (BSX) comes out ahead, leading on 9 of 9 compared factors.
Size & Scale
| ATRC | BSX | |
|---|---|---|
| Market Cap | $2.91 billion | $63.11 billion |
| Revenue (TTM) | $569.62 million | $21.00 billion |
| Net Income (TTM) | $10.55 million | $3.67 billion |
BSX leads on 3 of 3 size & scale factors.
Valuation
| ATRC | BSX | |
|---|---|---|
| P/E Ratio | 279.43 | 17.55 |
| Price / Book | 5.63 | 2.51 |
| Price / Sales | 5.10 | 3.01 |
BSX leads on 3 of 3 valuation factors.
Profitability
| ATRC | BSX | |
|---|---|---|
| Net Margin | 1.85% | 17.47% |
| Return on Equity | 2.04% | 14.58% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| ATRC | BSX | |
|---|---|---|
| Short Interest | 3.87% | 0.72% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ATRC overview, ATRC financials, BSX overview, BSX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.